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Abstract
Background:  To assess the long-term pediatric safety of 2 doses of mometasone furoate
administered via a dry powder inhaler (MF-DPI) for mild-to-moderate persistent asthma and
compare them with that of beclomethasone dipropionate administered via a metered dose inhaler
(BDP-MDI) in the treatment of persistent asthma. Both MF-DPI doses tested are twice the
approved pediatric dosage of 100 μg once-daily (QD) for children aged 4–11 years.
Methods: Children (N = 233) aged 4–11 years were randomized to 52 weeks of treatment with
MF-DPI 200 μg QD AM, MF-DPI 100 μg twice daily (BID), or BDP-MDI 168 μg BID. Patients had
used inhaled corticosteroids (ICSs) daily for ≥ 30 days before the screening visit and were on stable
ICS doses for ≥ 2 weeks before screening. The primary safety variable was the incidence of adverse
events. Secondary safety variables were laboratory tests (including cortisol concentrations), vital
signs, and physical examination.
Results:  The incidence of adverse events was similar in all 3 treatment groups. The most
frequently reported adverse event was upper respiratory tract infection, reported by 47%–49% of
the MF-DPI-treated patients and 51% of the BPD-treated patients. Most adverse events were
considered unrelated to study drug. The most frequently reported related adverse events were
headache (MF-DPI 200 μg QD AM, 8%; MF-DPI 100 μg BID, 4%; BDP-MDI 168 μg BID, 2%) and
oral candidiasis (4% in each treatment group). No clinically relevant changes in laboratory values,
including plasma cortisol, vital signs, or physical examinations were noted in any treatment group.
Conclusion: Both MF-DPI doses were well tolerated, with no unusual or unexpected adverse
events or safety concerns, and had a similar adverse event profile to that of BDP-MDI 168 μg BID.
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Background
Inhaled corticosteroids (ICSs) are considered to be the
most effective controller medication for children with
asthma.[1,2] However, safety concerns include their tran-
sient retardation of growth velocity and potential for
hypothalamic-pituitary-adrenal (HPA)-axis suppression.
The possibility of HPA-axis suppression is one of the more
important issues with the long-term use of ICS therapy
when high doses are used.
Mometasone furoate administered via a dry powder
inhaler (MF-DPI) is an ICS indicated for the maintenance
treatment of asthma in adults and children ≥ 4 years of
age. MF-DPI is available commercially as Twisthaler®. The
device has several features that make it attractive for use in
children. It is easy to use and delivers uniform doses
across inspiratory flow rates as low as 28.3 L/min.[3,4]
Three clinical trials in asthmatic adults have confirmed
that at therapeutic doses MF-DPI does not have clinically
meaningful effects on HPA-axis function as measured by
serum cortisol, which has been shown to be an accurate
measure of HPA-axis function. [5-7]
This study was designed to evaluate the long-term safety
of MF-DPI 200 μg once daily in the morning (QD AM)
and MF-DPI 100 μg twice daily (BID) against the safety
characteristics of beclomethasone dipropionate adminis-
tered via a metered dose inhaler (BDP-MDI) in children
with asthma requiring ICS therapy. The doses tested in
this clinical trial were twice the approved dose of 100 μg
QD PM for children ages 4–11.[8] The safety variables
evaluated over 1 year of treatment were adverse events
(AEs), vital signs, physical examination, and laboratory
tests (including analysis of plasma and urinary cortisol
concentrations).
Methods
The study was conducted in compliance with the human
experimentation guidelines of the US Department of
Health and Human Services and the Helsinki Declaration,
1975, last amended in Edinburgh, Scotland, 2000. The
protocol and consent form were approved by an Institu-
tional Review Board from each study center. Written
informed consent was obtained from parents or legal
guardians of each study participant.
Patient Population and Demographics
This was an open-label, multicenter, prospective study.
Children aged 4–11 years with a diagnosis of persistent
asthma of at least 6-months' duration participated in the
study. Eligible patients had a forced expiratory volume in
1 second (FEV1) of ≥ 60% of predicted at screening and
baseline. In addition, patients must have been using ICSs
for at least 30 days before screening, the regimen of which
must have been stable for at least 2 weeks before screen-
ing. Patients must have demonstrated evidence of an
increase in absolute FEV1 of ≥ 12% reversibility at screen-
ing or historically within the past 12 months and had
plasma cortisol levels at screening (8 AM ± 1 h) of ≥ 5 μg/
dL. Clinical laboratory tests (complete blood count,
blood chemistry, urinalysis) were required to be within
normal limits or clinically acceptable to the investigator.
Eligible female enrollees were premenarchal. Patients
were excluded if they had an upper- or lower-respiratory
tract infection within 2 weeks of screening or baseline vis-
its, demonstrated a ≥ 20% decrease in FEV1  between
screening and baseline visits, or received prohibited med-
ications including short-acting β-adrenergic inhaled bron-
chodilators within 6 hours, long-acting β2-agonist (LABA)
inhaled bronchodilators within 1 week, and systemic cor-
ticosteroids within 1 month of screening visit. Also
excluded were patients who required daily use of neb-
ulized β-agonists or LABAs to control asthma, patients
who had used >12 inhalations per day of albuterol on any
2 consecutive days between screening and baseline visits
and patients who were unable to use the MF-DPI device or
peak flow meter.
Study Design
Data were collected in the United States and Puerto Rico
between May 1998 and March 2000. After a 1- to 2-week
run-in period on stable doses of previous therapy, patients
were randomized to receive one of three treatments over a
period of 52 weeks: MF-DPI 200 μg QD AM, MF-DPI 100
μg BID (both twice the FDA approved dose), or BDP 168
μg BID (FDA approved). Office visits occurred at weeks 1,
2, 4, 8, 12, 16, 26, 38, and 52. Telephone contacts
occurred at weeks 20, 32, 42, and 48. An albuterol
metered-dose inhaler was provided at the screening visit
and enrollees were instructed to use it as needed, before
exercise, and before exposure to potential triggers (eg, ani-
mals). Patients were also instructed to withhold albuterol
use for at least 6 hours before each office visit. The use of
any LABA was prohibited for the duration of the study.
Study Medication
Patients received their first dose of study medication in
the investigator's office. For patients assigned to BID treat-
ment groups (MF-DPI 100 μg BID and BDP 168 μg BID),
if the baseline visit was held before noon, the first dose of
study medication (taken in the office) was to be consid-
ered the morning dose for that day; if the baseline visit
was held after noon, the first dose of study medication
(taken in the office) was to be considered the evening
dose for that day. For patients in the MF-DPI 200 μg QD
AM group, the first dose of study medication (taken in the
office) was to be considered their daily dose, independent
of the time of administration. Compliance was evaluated
throughout the study by asking the patient and/or the par-BMC Pediatrics 2009, 9:43 http://www.biomedcentral.com/1471-2431/9/43
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ent/guardian whether all medications had been taken as
instructed. The definition of noncompliance was the use
of <75% or >125% of the specified dose.
Safety Assessments
Safety was assessed by measuring the incidence and sever-
ity of AEs, vital signs, laboratory findings, and physical
examination, including oropharyngeal and ophthalmic
examination. Safety analyses were based on the intent-to-
treat-population, defined as any patient who took at least
1 dose of study medication. The primary safety criteria
were incidence and severity rates of AEs between groups.
AEs were judged by investigators to be not related, possi-
bly related, probably related, or related to therapy. Serious
adverse events (SAEs) were defined as AEs that were fatal,
life threatening, significantly or permanently disabling, or
resulting in inpatient or prolonged hospitalization. Inci-
dences of cancer, overdose (intentional or inadvertent), or
congenital anomalies were also considered SAEs. Asthma
worsening was defined as a ≥ 20% drop in FEV1 from base-
line; a clinical asthma exacerbation that required hospital-
ization, treatment with asthma medication other than
short-acting inhaled β-agonists, or any other emergency
treatment for asthma; a ≥ 25% drop in AM or PM peak
expiratory flow from the baseline AM PEF for 2 consecu-
tive days; Proventil® MDI use of ≥ 12 inhalations per day
for 2 consecutive days; or >2 treatments with nebulized
beta agonists on 2 consecutive days. Patients who experi-
enced asthma worsening may not have discontinued
study treatment. Patients were discontinued because of
significant asthma worsening if they required oral steroid
treatment for >15 days during the study if there was an
interval of ≥ 4 weeks between the last dose of systemic
steroid and 8 AM plasma cortisol and 12-hour urinary cor-
tisol testing; hospitalization for asthma occurred more
than twice; ventilator support was required; or chronic
treatment with additional ICSs was required. Morning (8
AM) plasma cortisol and 12-hour urinary cortisol levels
were measured at screening (plasma cortisol) or baseline
(urinary cortisol), week 26, and week 52 to evaluate HPA
axis function in patients at 10 preselected centers. MF-DPI
plasma concentrations were measured using predose sam-
ples collected at weeks 26 and 52; concentrations <50 pg/
mL were below the limit of quantitation. As this was pri-
marily a long-term safety study, the study was not
designed or powered to detect any treatment differences
in efficacy variables.
Statistical Analysis
Adverse events, vital signs, laboratory tests including 8 AM
plasma cortisol and 12-hour urinary cortisol concentra-
tions, and physical examination findings including
oropharyngeal and ophthalmic exam results were sum-
marized by treatment group. For vital signs and laboratory
tests, endpoint was defined as the measurement taken
closest to the last day of study treatment. Kaplan-Meier
estimates of time to first asthma worsening were calcu-
lated using the treatment day of the first observation of an
asthma worsening event and compared between treat-
ment groups using a log-rank test. Patients who met the
criteria for asthma worsening which required discontinu-
ation were classified as having been discontinued for the
purposes of this analysis, regardless of whether or not an
investigator actually discontinued the patient.
Results
Demographics
A total of 233 patients were enrolled and 190 patients
completed the study (Figure 1). Among all patients who
discontinued study treatment (n = 43), the most common
reason for discontinuation was noncompliance with pro-
tocol (n = 13; Figure 1). Baseline and postbaseline data for
plasma cortisol and 12-hour urinary cortisol were availa-
ble for 88 and 87 patients, respectively. The mean age in
each treatment group was approximately 8 years. The
majority of patients was boys (60%) and white (80%). A
detailed list of demographics and clinical characteristics of
the studied population are shown in Table 1.
Safety
The study drugs were both well-tolerated with similar AE
rates reported between treatment groups (Table 2). The
most frequently reported AE were upper respiratory tract
infections, reported by 47% to 51% of patients. Most AEs
were considered unrelated to study drug. The most fre-
quently reported related AEs were headache (MF-DPI 200
μg QD AM, 8%; MF-DPI 100 μg BID, 4%; BDP-MDI 168
μg BID, 2%) and oral candidiasis (4% in each treatment
group). The incidence of pharyngitis was also similar
among treatment groups. No deaths were reported
throughout the study. Few treatment interruptions or dis-
continuations due to AEs were observed. Five treated
patients (MF-DPI 200 μg QD AM, n = 3; MF-DPI 100 μg
BID, n = 1; and BDP 168 μg BID, n = 1) and 1 screening
patient experienced SAEs, however, none of these events
were considered to be related to treatment. Three patients
discontinued the study and 1 patient interrupted treat-
ment because of a SAE. Neither the number nor nature of
the SAEs reported suggested a differential risk of SAEs
among the treatment groups. AEs reported by ≥ 20% of
the study population are shown in Table 2.
The rate of clinical asthma exacerbations was similar
among treatment groups, and there were no differences
between treatment groups in the time to first asthma
worsening event (P = 0.370). The median times to first
asthma worsening event for the MF-DPI 200 μg QD AM,
MF-DPI 100 μg BID, and BDP-MDI 168 μg treatment
groups were 31, 35, and 17 weeks, respectively. Although
patients who experienced asthma worsening were notBMC Pediatrics 2009, 9:43 http://www.biomedcentral.com/1471-2431/9/43
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necessarily discontinued from the study, 2 patients receiv-
Patient disposition Figure 1
Patient disposition. AE = adverse event; BID = twice daily; BDP = beclomethasone dipropionate; MF-DPI = mometasone 
furoate administered via a dry powder inhaler; QD AM = once daily in the morning.
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Table 1: Baseline Patient Demographics and Clinical Characteristics
Demographic or Characteristic MF-DPI
200 μg QD AM
(n = 78)
MF-DPI
100 μg BID
(n = 74)
BDP
168 μg BID
(n = 81)
Age, mean y 8.4 8.1 8.0
Sex, n
Girls 35 26 32
Boys 43 48 49
Race, n
White 66 61 64
Other 12 13 17
Weight, mean kg 34.1 33.2 32.3
Asthma duration, mean y 5.3 4.8 5.1
Theophylline use, n 1 2 0
Baseline % predicted FEV1, mean 85.2 86.1 87.4
BID = twice daily; BDP = beclomethasone dipropionate; FEV1 = forced expiratory volume in 1 second; MF-DPI = mometasone furoate administered 
via a dry powder inhaler; QD AM = once daily in the morning.BMC Pediatrics 2009, 9:43 http://www.biomedcentral.com/1471-2431/9/43
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ing MF-DPI 200 μg QD AM, 2 patients receiving MF-DPI
100 μg BID, and 3 patients receiving BDP 168 μg BID dis-
continued due to asthma worsening. No significant
changes among treatment groups were observed in the
mean 8 AM plasma cortisol levels from baseline even
though the doses tested (ie, MF-DPI 200 μg QD AM and
MF-DPI 100 μg BID), were twice as much as the approved
doses (Figure 2A). The 12-hour urinary cortisol adjusted
for creatinine (UCCR) was similar between treatment
groups at endpoint, with mean values of 3.69 nmol/
mmol for the BDP 168 μg BID group, 3.12 nmol/mmol
for the MF-DPI 200 μg QD AM group, and 3.67 nmol/
mmol for the MF-DPI 100 μg BID group (Figure 2B).
Plasma samples were collected for measuring MF-DPI
concentrations from a total of 92 patients (MF-DPI 100 μg
BID, n = 30; MF-DPI 200 μg QD AM, n = 34; BDP 168 μg
BID, n = 28). At weeks 26 and 52, predose plasma MF-DPI
concentrations were below the limit of quantitation in the
majority of patients who were randomized to receive MF-
DPI (MF-DPI 100 μg BID, 88% [week 26], 93% [week 52];
MF-DPI 200 μg QD AM, 78% [week 26], 93% [week 52]).
As expected, no patient in the BDP 168 μg BID treatment
group had a plasma MF-DPI concentration above the
limit of quantitation.
Discussion
This study evaluated the safety of MF-DPI at doses twice as
high as the approved dose of 100 μg QD for children. BDP
was chosen as the active comparator because it is an estab-
lished corticosteroid used in treating asthma in children.
The dose of BDP used during the clinical trial was the
approved dose. A limitation of the study is that it evalu-
ated the CFC formulation of BDP, which is no longer mar-
keted. However, BDP-CFC is an established reference
standard and its use as a comparator for adverse events
and time to first exacerbation remains valid. Another lim-
itation is the open-label design of the study, which may
Table 2: Adverse Events in ≥ 20% of Study Population
Adverse Event, n (%) MF-DPI
200 μg QD AM
(n = 78)
MF-DPI
100 μg BID
(n = 74)
BDP
168 μg BID
(n = 81)
Allergy 22 (28) 11 (15) 20 (25)
Fever 18 (23) 20 (27) 26 (32)
Headache 33 (42) 27 (36) 25 (31)
Viral infection 27 (35) 26 (35) 29 (36)
Nasal congestion 7 (9) 17 (23) 11 (14)
Pharyngitis 26 (33) 25 (34) 25 (31)
Rhinitis 29 (37) 20 (27) 22 (27)
Sinusitis 15 (19) 15 (20) 11 (14)
Upper respiratory tract infection 38 (49) 35 (47) 41 (51)
BID = twice daily; BDP = beclomethasone dipropionate; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD AM = once 
daily in the morning.
(A) 8 AM plasma cortisol levels and (B) 12-hour urinary free  cortisol levels adjusted for creatinine (UCCR) at baseline and  endpoint Figure 2
(A) 8 AM plasma cortisol levels and (B) 12-hour uri-
nary free cortisol levels adjusted for creatinine 
(UCCR) at baseline and endpoint. Endpoint was defined 
as the measurement taken closest to the last day of study 
treatment. Bars indicate means + standard deviations. BID = 
twice daily; BDP = beclomethasone dipropionate; MF-DPI = 
mometasone furoate administered via a dry powder inhaler; 
QD AM = once daily in the morning.
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have introduced bias in regards to subjective outcomes
such as patient reporting of adverse events. An open-label
study design was employed so that the study could be
amended or terminated if any treatment groups experi-
enced unexpected trends in the incidence or severity of
adverse events while the study was ongoing. Although
inability to use MF-DPI device or peak flow meter was a
basis for exclusion from this study, it must be emphasized
that a majority of children are able to use the inhaler
device correctly.
MF-DPI 200 μg QD AM and MF-DPI 100 μg BID dosing
strategies were well tolerated and had similar AE profiles
to BDP 168 μg BID. No clinically significant changes in
laboratory parameters, vital signs, or physical examina-
tion findings over the course of the study in any treatment
group were observed. Although the original study proto-
col called for the evaluation of HPA-axis effects with
adrenocorticotropic hormone (ACTH)-stimulated cortisol
testing, the protocol was amended such that 8 AM plasma
cortisol and 12-hour UCCR replaced ACTH stimulation
for cortisol testing. High baseline urinary cortisol levels
were observed and notable variations in 12-hour UCCR
levels were evident between patients, which accounted for
the relatively large standard deviations for mean 12-hour
UCCR values. This variability may have been due to the
inherent shortcomings associated with a 12-hour urine
collection period versus a more accurate 24-hour urine
collection period. Overall, urine volumes tended to be
lower at follow-up visits than at baseline and in some
cases showed extreme change from the baseline volume,
which suggests that urine collections may have been
incomplete in the home environment. No significant dif-
ferences between treatments were observed for 8 AM
plasma cortisol levels at weeks 26, 52, and endpoint.
These results are consistent with previous studies of ICS
therapies in pediatric populations, [9-13] although acute
adrenal crisis has been previously reported in children
receiving high doses of several ICSs, including beclometh-
asone dipropionate and budesonide, but primarily fluti-
casone propionate.[14]
The results of the current study are similar to those from
another clinical trial designed to evaluate the HPA-axis
effects of 29 days of treatment with MF-DPI 100 μg BID,
200 μg BID, 400 μg BID, or placebo in children ages 6–11
years.[15] The MF-DPI 100 μg BID and 200 μg BID doses
had no statistically significant effects on the 12-hour
plasma cortisol area under the curve (AUC) compared
with placebo. However, the MF-DPI 400 μg BID dose (8
times the approved dosage) significantly decreased the
12-hour AUC (P = 0.05). At day 29, cosyntropin stimula-
tion responses were not significantly different between
any of the treatment groups. No clinical AEs related to
adrenal function were seen in the MF-DPI 400 μg BID
group or any other, which indicates a wide HPA-axis
safety margin for MF-DPI in children.
In a separate 52-week safety study of the impact of MF-
DPI 100 μg BID, MF-DPI 100 μg QD AM, or MF-DPI 200
μg QD AM versus placebo on growth velocity and the HPA
axis in 187 children (aged 4–9 y) with mild persistent
asthma, MF-DPI did not show an effect on the HPA
axis.[16] At the end of the treatment period, mean plasma
cortisol values were highest in the 100-μg QD AM group,
followed (in descending order) by the 100 μg BID, 200 μg
QD AM, and placebo groups.
The effect of mometasone furoate on the HPA axis in chil-
dren has also been studied using a metered dose inhaler
formulation (MF-MDI). In a 52-week trial, 205 steroid-
naive children (aged 4–9 y) with mild persistent asthma
received MF-MDI 100 μg QD PM, MF-MDI 100 μg BID, or
placebo.[17] Cortisol testing showed no HPA-axis effects
with MF-MDI at any dose.
Conclusion
These findings suggest that long-term treatment with MF-
DPI 200 μg QD AM or MF-DPI 100 μg BID is safe in pedi-
atric patients with persistent asthma who require ICS ther-
apy, with no significant effects on HPA-axis function over
at least 1 year. The doses tested here were twice as high as
the 100 μg QD dose approved for children 4–11 years old.
The AEs associated with MF-DPI use in children were sim-
ilar to those observed when children are treated with BDP.
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